In	O
the	O
United	COUNTRY
States	COUNTRY
,	O
Tricor	ORGANIZATION
was	O
reformulated	O
in	O
2005	DATE
.	O
This	O
reformulation	O
is	O
controversial	O
,	O
as	O
it	O
is	O
seen	O
as	O
an	O
attempt	O
to	O
stifle	O
competition	O
from	O
generic	O
equivalents	O
of	O
the	O
drug	O
,	O
and	O
is	O
the	O
subject	O
of	O
antitrust	O
litigation	O
by	O
generic	O
drug	O
manufacturer	TITLE
Teva	ORGANIZATION
.	O
Also	O
available	O
in	O
the	O
United	COUNTRY
States	COUNTRY
,	O
Lofibra	LOCATION
is	O
available	O
in	O
54	NUMBER
and	O
160	NUMBER
mg	O
tablets	O
,	O
as	O
well	O
as	O
67	NUMBER
,	O
134	NUMBER
,	O
and	NUMBER
200	NUMBER
;	O
mgmicronized	O
capsules	O
.	O
Generic	O
equivalents	O
of	O
Lofibra	LOCATION
capsules	O
are	O
currently	O
available	O
in	O
all	O
three	NUMBER
strengths	O
in	O
the	O
United	COUNTRY
States	COUNTRY
.	O
In	O
Europe	LOCATION
,	O
it	O
is	O
available	O
in	O
either	O
coated	O
tablet	O
or	O
capsule	O
;	O
the	O
strength	O
range	O
includes	O
67,145	NUMBER
,	O
160	NUMBER
and	O
200	NUMBER
mg	O
.	O
The	O
differences	O
among	O
strengths	O
are	O
a	O
result	O
of	O
alteredbioavailability	O
due	O
to	O
particle	O
size	O
.	O
For	O
example	O
,	O
200	NUMBER
mg	O
can	O
be	O
replaced	O
by	O
160	NUMBER
mg	O
micronized	O
fenofibrate	O
.	O
The	O
145	NUMBER
mgstrength	O
is	O
a	O
new	O
strength	O
that	O
appeared	O
in	O
2005-2006	DURATION
which	O
also	O
replaces	O
200	NUMBER
or	O
160	NUMBER
mg	O
as	O
the	O
fenofibrate	O
is	O
nanonised	O
-LRB-	O
i.e.	O
the	O
particle	O
size	O
is	O
below	O
400nm	O
-RRB-	O
.	O